About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 3NCT01001988

Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers

This is a long-term follow-up of the persistence of immune response in participants who previously received a single dose of JE-CV at age 12 to 18 months in Study JEC02 (NCT00735644) . No vaccination ...

Lead sponsor: Sanofi Pasteur, a Sanofi Company•4 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Sanofi Pasteur, a Sanofi Company

Persistence of immune response will be determined in participants who previously received a single dose of JE-CV at age 12 to 18 months in Study JEC02 (NCT00735644). No vaccination will be given in this study.

Age

2 - 3 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Provision of Informed Consent Form signed by at least one parent or other legally acceptable representative, and by at least one independent witness if required by local regulations.
•Participant who was vaccinated with JE-CV in JEC02 trial and had a pre-vaccination blood sample at baseline in JEC02 trial.
•Participant and parent/legally acceptable representative able to attend all scheduled visits and comply with all trial procedures.

Exclusion Criteria

•Receipt of any JE vaccine other than JE-CV during JEC02 trial and during the period up to inclusion in JEC05 trial.
•Planned participation in another clinical trial up to the first year of the follow-up in the present trial.

Related studies

FDG-PET in the Diagnosis of Autoimmune Encephalitis

NCT06019975 · Autoimmune Encephalitis

Study of Pathogenic Mechanisms and Identification of Novel Autoantibodies in Autoimmune Encephalitis

NCT07477015 · Autoimmune Encephalitis

Long-term Impact of NMDAR Encephalitis, Level 3

NCT07158229 · NMDAR Autoimmune Encephalitis

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT04806620 · Post-Acute COVID-19 Syndrome, ME/CFS, and more

RECRUITINGPhase 1/2

SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy

NCT05586581 · HIV Associated Neurocognitive Disorder, HIV Dementia, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 29, 2017Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment596

Start dateAug 2009

Last updatedNov 29, 2017

Condition

Encephalitis Japanese Encephalitis

Locations shown

City of Muntinlupa

Bangkok

Bangkok

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 29, 2017Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions